Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MEI Pharma, Inc. - Common Stock (NQ:MEIP)

2.890 -0.110 (-3.67%)
Streaming Delayed Price Updated: 10:37 AM EDT, Sep 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MEI Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
MEI Pharma, Kyowa Kirin Reveal Data From Zandelisib Trial In Follicular Lymphoma
MEI Pharma Inc (NASDAQ: MEIP) and Kyowa Kirin Co Ltd have announced data from the pivotal Phase 2 TIDAL study of zandelisib as a single agent for follicular... 
Via Benzinga
The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Cumberland Gets FDA Approval For IV-Delivered Ibuprofen For Use In Pre-... 
Via Benzinga
MEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as a Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma to Host Webcast on November 30, 2021 at 8:00 a.m. ET Reporting Data from Ongoing Global Phase 2 TIDAL Study of Zandelisib in Patients with Follicular Lymphoma
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Appoints Biotechnology Executive Sujay Kango to its Board of Directors
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Reports First Quarter Fiscal Year 2022 Results and Operational Highlights
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma and Kyowa Kirin receive Orphan Drug Designation for Zandelisib for the Treatment of Follicular Lymphoma
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Announces Acceptance of Three Abstracts for Presentation at the 63rd Annual American Society of Hematology Annual Meeting
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From MEI Pharma, Inc.
Via Business Wire
40 Biggest Movers From Yesterday
Gainers Volcon, Inc. (NASDAQ: VLCN) shares jumped 97.5% to settle at $10.86 on Wednesday as the company priced its IPO at $5.50 per share. Voyager Therapeutics, Inc. (NASDAQ:... 
Via Benzinga
Topics Initial Public Offering
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Voyager Therapeutics (NASDAQ:VYGR) shares moved upwards by 44.73% to $3.58 during Wednesday's regular session. Voyager Therapeutics's stock is trading at a... 
Via Benzinga
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From MEI Pharma, Inc.
Via Business Wire
Earnings Scheduled For September 2, 2021
Companies Reporting Before The Bell • Navios Maritime Holdings (NYSE:NM) is projected to report earnings for its second quarter. • WisdomTree International... 
Via Benzinga
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) AbbVie Inc. (NASDAQ: ABBV... 
Via Benzinga
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,... 
Via Benzinga
77 Biggest Movers From Yesterday
Gainers AMC Entertainment Holdings, Inc. (NYSE: AMC) shares surged 23.7% to close at $12.77. Moxian, Inc. (NASDAQ: MOXC) jumped 23.6% to close at $9.52. Repro Med Systems, Inc... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.